Trestle Biotherapeutics

About:

Trestle Biotherapeutics is a biotechnology company that introduces bioengineered kidneys for patients with kidney disease.

Website: http://www.trestlebio.com/

Top Investors: Y Combinator, Sahin Boydas, Acequia Capital (AceCap), Asymmetry Ventures, FAST — by GETTYLAB

Description:

Trestle Biotherapeutics is a biotechnology company that introduces bioengineered kidneys for patients with kidney disease. The company's services allow healthcare providers to reduce their reliance on dialysis while also enhancing the disease status of renal patients through the combination of stem cell biology and bio-fabrication. Trestle Biotherapeutics was founded in 2020 by Alice Chen and Ben Shepherd and is based in San Diego, California, United States.

Total Funding Amount:

$1M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Diego, California, United States

Founded Date:

2020-01-01

Founders:

Alice Chen, Ben Shepherd

Number of Employees:

1-10

Last Funding Date:

2023-06-12

IPO Status:

Private

Industries:

© 2025 bioDAO.ai